Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (July 2026)
66 slides from Genprex's investor presentation, Jul 14, 2026
Slide 1: Pioneering Gene Therapies for Patients in Need
€) Genprex’ Pioneering Gene Therapies for Patients in Need July 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements “Yorwordiooing semen within de meaning fhe Private Scuties Ligation Refem Aa of 1995 Becnuce uch savers are subjectto ris anduncrece, cul ests may der raters am the expend or pled auc foarlosking arent Such aatements Include but arent ited, saxerent tering ur expected pera
Slide 3: Our Mission
Our Mission Advancing novel gene therapies for patients afflicted with cancer or diabetes. © Genprex’
Slide 4: Program Highlights
Program Highlights ONCOLOGY DIABETES (@) Non-viral gene therapy platform (@) Addressing both Type 1 and Type 2 diabetes with AAV gene therapy Novel approach using systemic gene therapy to replace tumor suppressor genes for cancer in @ Novel infusion process delivers genes to pancreas. humans a Demon
Slide 5: Research and Development Pipeline
Research and Development Pipeline
Slide 6: Oncology
Q ONCOLOGY REPROGRAMMING THE COURSE OF CANCER Cry} www.genprex.com
Slide 7: Why TUSC2?
Why TUSC2? Discovery Tumor Suppressor Candidate 2 Chromosome 3p21.3 deleted gene Previously called FUS1 NPRL2 is in the same area of the chromosome © Genprex Tumor Suppressor Gene TUSC2 restoration in cancer cells in vitro inhibits cell growth and induces apoptosis TUSC2 is encoded by nuclear DNA bu
Slide 8: Tumor Suppressor Genes Deleted During Cancer Development
Tumor Suppressor Genes Deleted During Cancer Development ‘© Tumor suppressor genes are deleted early during cancer development. © 82% of all non-small cell tung cancers and 100% of all small-cell lung cancers express decreased amounts of TUSC2 ‘tumor suppressor protein + Loss or reduction of TUSC2 e
Slide 9: Oncoprex Delivery System
Oncoprex® Non-viral, positively-charged lipid-based nanoparticle in a lipoplex form is systemically Delivery System delivered. NON-VIRAL DELIVERY OF TUMOR SUPPRESSOR GENE O Genprex Cationic lipoplex carries drug to tumors.
Slide 10: Our Cancer Treatment Approach
Our Cancer Treatment Approach ‘Tumor Suppressor Gene in a DNA Plasmid Tumor suppressor genes are deleted early during cancer development. + Our method of treating cancer is to reintroduce tumor ; ee suppressor genes to patients. Systemic Patient Administration See eae cancer cal. pecficaly targets ©
Slide 11: Novel Platform to Treat Cancer
Novel Platform to Treat Cancer © Genprex Systemic Gene Therapy Platform: Oncoprex® Delivery System Genes Allows for delivery of TUSC2 and NPRL2 genes and potentially a variety of other genes Syner Can be used in combination with other cancer therapies such as Tagrisso® and Tecentriq?® Cancers Data i
Slide 12: Reqorsa Targets Cancer At Its Core
Regorsa® Targets Cancer At Its Core (i | eS Controls Cell Signaling Tyrosine kinase inhibition decreases cancer cell proliferation © Genprex’ Stimulates Apoptotic Pathways Leads to programmed cancer cell death Multiple anti-cancer mechanisms of action. oe Modulates Immune Response Promotes immune ac
Slide 13: Reqorsa Reduces Glycolysis in Cancer Cells
a ' Reqorsa® Reduces Glycolysis in REQ ORSA Reverses Fundamental Cancer Cells Cancers are detected by PET scans + PET scanning is based on increased glucose uptake in cancer cells + Due to high rate of glycolysis in cancer cells + Increased glycolysis is found in virtually all cancers. A549 cells ar
Slide 14: Lung Cancer: By the Numbers
Lung Cancer: By the Numbers 124K $104B 28% e e e e U.S. Annual Global Lung Global U.S. Lung U.S. Average Mortality ‘Cancer Incidence Market Cancer Incidence —_ Lung Cancer Survival More th: milo Global markets projected Rate year to grow from $18.3bilion in le 2018 t0$104 billion by 2032 © Genprex
Slide 15: Reqorsa Monotherapy ONC-001 Trial
Reqorsa® Monotherapy ONC-001 Trial DOSE ESCALATION STUDY Explored toxicity and tolerability in patients. Phase 1 monotherapy results: + 31 Stage IV lung cancer patients + 0.01 - 0.09 ma/kg + 23 patients evaluable + 5 patients had stable disease + 2 patients had tumor shrinkage + Generally well-toler
Slide 16: Selective Uptake of Reqorsa
Selective Uptake REQORSA Targets Cancer Cells of Regorsa® Pretreatment Biopsies Posttreatment Biopsies REQORSA is designed to detiver functioning TUSC2 gene to cancer minimizing its uptake by norm: > Patient 1 (02 mg/kg) (ow that, in three the expression of TUSC ed 1 day after REQC Patient 2 treat (
Slide 17: Reqorsa + Tarceva ONC-002 Phase 1/2 Trial
® Regorsa® + Tarceva ONC-002 Phase 2 Trial Met Simon 2-stage criteria to enroll the full 39 subjects, but was discontinued to start study with Tagrisso. Wetegeonae soeet twron Geman) 2 eegenen soos Negrve Ceroiameo vssegtaone 2 tye css, i : eetinene 2 soe fe) (em 2 soot see ome 2 FA soe ne creme ‘ ©
Slide 18: Drug resistance to Tagrisso and Tecentriq is inevitable
For most patients, drug resistance to Tagrisso® and Tecentrig® is inevitable. 2? Our approach is designed to address drug resistance. REQORSA Immunogene Therapy may be complementary with targeted drugs and immunotherapies. REQORSA's multimodal activity may block emerging bypass pathways, thereby pot
Slide 19: Reqorsa + Tagrisso Reduce Tumor Growth in Resistant Tumors
© Genprex Reqgorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors Enhanced Anti-Tumor Activity REQORSA in combination with ry Tagrisso demonstrated z significantly increased anti-tumor A i efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975- ile OsiR mouse xenografts. et t
Slide 20: Acclaim-1: Reqorsa with Tagrisso in EGFR mutant NSCLC
Patients with advanced, EGFR mutant NSCLC whose disease Fe oe eg eee aera eee oraien ripe. Hoogy Al int FDA Fast Track Designation bf ded ee Acclaim - 1 ¢ Phase 1 Dose Escalation: 12 patients (completed) © Phase 2a Expansion: ~33 patients (currently enrolling) Evaluating enrollment criteria based on
Slide 21: Phase 1 Dose Escalation
Phase 1 Dose Escalation Enrollment and Dose Limiting Toxicities 206matg ——0BmpNg «OR mag Total Patate 3 * Ey 2 Medan Aoeane) 5915060) S186 S07-7 59879 bute ° ° ° ° Progression Free Survival by Dose Group PFS das) {omer wincow ang pater mos et ow ble copltng tit ad arte want eval PS Excellent safety
Slide 22: Predictive Biomarkers for PFS in Patients Receiving Reqorsa
Predictive Biomarkers for PFS in _,, My Predict Patient Response, . Pa nable Targeted Patient Selection Patients Receiving Reqorsa® and Allow for Precision Medicine. High Trop-2 Expression and Low PTEN Expression Correlated With Longer Progression Free Survival (PFS) in NSCLC Patients Data from 18 c
Slide 23: Reqorsa in Small Cell Lung Cancer
Regorsa® in Small Cell Lung Cancer Targeting Small Cell Lung Cancer (in addition to NSCLC) allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: Consistently has low TUSC2 protein levels 2 Documented to often have deletion of at least one TUSC2 gene allele ‘Sal
Slide 24: SCLCs Express Low Levels of TUSC2 Protein
SCLCs Express Low Levels Of TUSC2 Protein IHC analysis of tumor specimens Since all SCLCs have reduced or no TUSC2 41% of SCLC have no TUSC2 protein expression protein expression, re-expressing TUSC2 100% of SCLC have reduced or no TUSC2 protein protein may lead to clinical efficacy. expression Hist
Slide 25: Tecentriq (atezolizumab) SCLC Approval Trial
Tecentriq® (atezolizumab) SCLC Approval Trial IMpower133 Study Adding Tecentriq to standard therapy improves survival in SCLC and establishes a new standard therapy for ES-SCLC. © Untreated, extensive stage SCLC © Carboplatin & etoposide chemotherapy + atezolizumab or placebo + 4cycles, then atezoli
Slide 26: Atezolizumab Maintenance Therapy
Atezolizumab Maintenance Therapy Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very short (2.6 mos). poll Unstatied HR, 0.66 (05% Cr: 052-088 Atezolizumab vs placebo AILCR, PR, and SD patients received maintenance therapy + Endpoints measured from the start of
Slide 27: Reqorsa Adds Significantly to Tecentriq Treatment
Reqorsa® Adds Significantly to Tecentriq Treatment CONTROL REQORSA H841 SCLC cell xenografts in humanized mice REQORSA + Atezo on H841 SCLC ‘Lung Met in Humanized Mice [003 CConvol —AtezoREQORSA Combination At Week #3
Slide 28: Increased Immune Response with Reqorsa and Tecentriq
Increased Immune Response with Regorsa® and Tecentriq © Genprex
Slide 29: Acclaim-3: Reqorsa with Tecentriq in ES-SCLC
Patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq® and chemotherapy “suit? 5 510-15US ates ccidl © ~62 patients © Phase 1 Dose Escalation: (completed) © Phase 2: ~50 patients (currently enrolling) © Phase 2 interim analysis after 25th patient enrolled and treated
Slide 30: Reqorsa in Ras Inhibitor Resistant Lung Cancer
Regorsa® in Ras Inhibitor Resistant REQORSA effectively overcomes sotorasib AR in Lung Cancer KRASG12cmutant NSCLC mouse xenografts Published Results: + Researchers demonstrated that REQORSA, alone or in combination ‘with sotorasib inhibited colony formation, induced apoptosis, and showed significan
Slide 31: Reqorsa in ALK-EML4 Positive Translocated Lung Cancer
Regorsa® in ALK-ELM4 Positive License Agreement and SRA with The University of Translocated Lung Cancer Michigan Rogel Cancer Center and Collaboration with ALK- Positive Advocacy Group Published Results: ALK-Positive Collaboration: REQORSA induced apoptosis in lectins =) Net eft tentative escerch fe
Slide 32: Reqorsa in ALK Xenograft Model
Reqorsa® in ALK Xenograft Model NCI-H2228 xenograft REQORSA markedly decreases growth of ALK- sensitive xenografts in mice ; + Both as single agent and in combination Hi with alectinib 3 mt Tumor Shrinkage (96) Regorsa + vehicle 788 ue (© BNP svehice contrat BNP SAlectiniy BNP + alectinib 60.14 1m R
Slide 33: Reqorsa in Mesothelioma
Regorsa® in Mesothelioma Published Results: + Researchers investigated whether TUSC2 transfection could modulate MPM agaressive properties + FourMPM cell tines and tert- transformed mesothelial LP9 cells were treated with REQORSA and control liposomes for 48h. Treated cells were then evaluated for T
Slide 34: NPRL2 Induces Anti-tumor Activity in NSCLC
NPRL2 Induces Anti-tumor Activity in NSCLC Further Evidence of Oncoprex® Delivery System as a Platform for Treatment Using Tumor Suppressor Genes Study investigated the antitumor responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC in a humanized mouse model Humanized mice w
Slide 35: Combined TUSC2 and NPRL2 Re-Expression in SCLC
Combined TUSC2 and NPRL2 Re-Expression in SCLC H841 lacks both TUSC2 and NPRL2 protein Increased control of xenograft growth compared to: Controt + TUSC2 re-expression alone NPRL2 re-expression alone © Genprex “Tumor Volume (mm) TUSC2+NPRL2 Dual Gene Therapy Combination on inflamed H841 Tumors in Hu
Slide 36: Diabetes
Q DIABETES www.genprex.com
Slide 37: Diabetes: By the Numbers
Diabetes: By the Numbers 40M $37B e e e e Diabetes U.S. Diabetes Global Global Diabetes T2D Global Market _T1D Global Market Prevalence? Prevalence? Expenditures? (7.05% CAGR‘)_—_(17.2% CAGR®) NSMUS. adult Expes ed at least USD JUS. marke O85IMby Diab Tteilion us. $708 expe expenditure ~ © Genprex
Slide 38: Diabetes can cause serious complications
Diabetes can cause serious complications. In 2024, there was approximately 1 death every 9 seconds caused by diabetes worldwide. © Genprex
Slide 39: Diabetes Causes Serious Complications
Diabetes Causes Serious Complications Heart Disease Leading cause of death for men and women in US. Diabetics are 2x as lkely to have heart disease or a stroke. Chronic Kidney Disease ‘Approximately 1 in 3 adults with diabetes have CKD. Kidney diseases are the Sth leading cause of death in US. Nerve
Slide 40: Diabetic Patients Are In Need of Advanced Therapy
Diabetic Patients Are In Potential for disease modification Need of Advanced Therapy for long-term effectiveness. s Patients suffer compromised quality of life Despite certain advancements in treatment, quality, of fe remains highly compromised for many individuals with diabetes. hese cells resulted
Slide 41: Novel Gene Therapy Diabetes Program
Novel Gene Therapy License Agreement and SRA with University Diabetes Prog ram of Pittsburgh intends to address both T1D and T2D. 38M or 11.6% of Americans Have Diabetes! Type 1 Diabetes (5-10%) ———e ° Type 2 Diabetes (90-95%) Inability ofthe pancreas to produce enough Insulin due largely to resista
Slide 42: GPX-002 Replenishes Insulin Producing Cells
GPX-002 Replenishes Insulin Producing Cells Delivers Genes to the Pancreas n AAV ector to deliver the Hyperelycemia Reprograms Alpha Cells transforms alpha cells wea? Beta-cell Aeficiency Restores Blood Glucose Levels In vivo, preclinical studies show that GPX.002 restored normal blood glucose level
Slide 43: Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model
Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model Blood glucose (md) ‘beta cllmass g) : stloxan AAV-8 nection Untreated alloans alloxan ‘Group Reprogramed alpha cells into beta-like cells that appropriately produce insulin in response to glucose levels. Normalized blood glucose in beta
Slide 44: Restored Blood Glucose in T1D Autoimmune Mouse Model
Restored Blood Glucose in T1D In Autoimmune Mouse Model for Four Months The duration of restored blood 10 glucose levels in mice could r potentially translate to decades in humans. os beta cel maze (mg) One week in a mouse tends to correlate to about one year in humans. Blood glucose (mgt) NOD mice
Slide 45: Induced Generation of Insulin-Expressing Cells from Alpha Cells in Human Islets
Induced Generation of Functional Insulin-Expressing Cells from Alpha Cells in Human Islets Provides a potential basis for further investigation in human Type 1 diabetes Human islets treated with streptozotocin oo to to destroy beta-cells, then treated with either AAV-PM or AAV-GFP AAV treated islets
Slide 46: Non-Human Primate Model of T1D
Non-Human Primate Model of T1D Reduced Insulin Requirements © Genprex’ veatintiton f NHP 4 insulin / Carb isl ll | | | Mul alii 150 E 100 § 050 : 0.00 Viral Infusion NHP2 are | lh loi iii i $ 150 % 100 § 050 i 000 Data from University of Pittsburgh researchers show a marked reduction in insulin requ
Slide 47: Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs
Decreased Insulin Requirements and Improved Glucose Tolerance in NHPs Following the pancreatic intraductal infusion of the AAV engineered construct, the eight Z NHPs had: Decreased insulin requirements (p<0.001) Increased ¢-peptide levels (p<0.05) Improved glucose tolerance compared to baseline (p<0
Slide 48: NHP2 Three-Month Glucose Tolerance Test
NHP2 Three-Month Glucose Tolerance Test “© Pre Gene Therapy ‘Post Gene Therapy (3 months) Normal NHP- z 3 — eo ri ——+ 8 co . 2 oe 0 20 40 60 Time (min) © Genprex
Slide 49: IHC Eight Weeks After Gene Therapy
DAPI IHC Eight Weeks After Gene Therapy Normal NHP Genprex: Need at least 20% of normal beta cell mass to Diabetic NHP Without Gene Therapy maintain normoglycemia Diabetic NHP After Gene Therapy
Slide 50: Rejuvenates Exhausted Beta Cells in T2D NHP Models
Rejuvenates Exhausted Beta Cells in T2D NHP Models NHP 1 ‘AAV infusion into the pancreatic duct Improved glucose tolerance testing over several months ‘At seven months, NHP had normal glucose tolerance testing Decrease in insulin requirements Intraductal infusion is superior to direct injection NHP
Slide 51: Reversed Hyperglycemia in Type 2 Diabetic Mouse Models
Reversed Hyperglycemia in Type 2 Diabetic Mouse Models Treatment of high fat diet (HFD) mice with RIP-PM-GFP, which : poor selectively targets B-cells, G normalized glucose tolerance testing (GTT) and improved ex-vivo glucose-stimulated insulin secretion (GsIs), PM gene therapy in HFD mice normalize
Slide 52: Studying GPX-002 Using a Lipid Nanoparticle
Studying GPX-002 Using a ele Poteet Fe Dosing Ua Lipid Nanoparticle ee et Eaien Oaen New studies use an alternative second generation approach with a non-viral id nanoparticle delivery system First and only company to research diabetes gene therapy using a lipid nanoparticle in place of a viral AAV
Slide 53: Corporate
Q CORPORATE www.genprex.com
Slide 54: Our Team: Company Management
Our Team: Company Management 22 a ob
Slide 55: Our Team: Scientific Advisory Board
Our Team: Scientific Advisory Board George Simon George k Gates
Slide 56: Our Team: Clinical Advisory Board
Our Team: Clinical Advisory Board mM 2.
Slide 57: Our Team: Board of Directors
Our Team: Board of Directors eae
Slide 58: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones Acclaim -1 Acclaim -3 Open for enrollment in Phase 2 Expansion portion of the trial Expect to open additional sites by the end of 20 smplete enrollment of atkers to optimize first 25 patientsin Phase 2 studies Expansion Portion byend of 2026 for term anal Phase 2in
Slide 59: We believe in a future of transformational patient care
We believe in a future of transformational patient care. 21 Century Large Combination Two FDA Gene Markets & | Trials with Top Fast Track Therapies Unmet Need | SellingDrugs | Designations Exploring New Indications & Partnerships
Slide 60: Slide 60
Slide 61: Research References
Research References Slide 7 1. Wistuba I, Behrens c Virani AK. etal. High resolution chromosome 3p <llelotypirg of human lung cancer and preneoplastcireinvasive bronchial ’epithelium reveals multple.dscontinuousstes ofp allele oss and three regions of frequent breskpoints. Cancer Res. 2000:60(71948-
Slide 62: Research References
Research References Slide 36 1. Centers for Disease Control (2026: httosfiLv/éclage 2. International Diabetes Federation (2025): bina. W/Achzvid 3. IDF Diabetes Atlas (2025) hits. ylatGP 2c 4. Precedence Research: htps/faW/abVIAN 5. Precedence Research: itps./bi.WamaTsuy Slide 37 1. Centers for Dise
Slide 63: Appendix
a) APPENDIX
Slide 64: Reqorsa + Keytruda Significantly Reduced Tumor Growth
Regorsa® + Keytruda® REQORSA increases immune response Significantly Reduced Tumor Sees Shee tenet Growth REQORSA + Keytruda® The independent immunologic effects of REQORSA and Keytruda markedly decrease tumor growth by increasing the immunologic attack on the tumor compared to PD-1 inhibition alone
Slide 65: AACR 21: Reqorsa May Enhance First-Line Standard of Care
AACR 21: Regorsa® May Enhance First-Line Standard of Care Reqorsa® + Keytruda® + Chemo fegonsa sxtor | Eoportono + Eiaspeebetncgonsa REQORSA enhances the efficacy of =| y, chemo-immunotherapy on KRAS-LKB1 (KL)-mutant lung metastases in humanized mice. Tota Fx fs) Triple combination demonstrated stro
Slide 66: Acclaim-2 is no longer enrolling new patients
Acclaim-2 is no longer enrolling new patients. atte esl! Overview of the former trial: Acc | aim- 2 © Patients with advanced NSCLC whose disease progressed after treatment with Keytruda® . » FDA Fast Track Designation Regorsa! in combination with Merck & Co's Keytruda® for NSCLC Phase 2b: Comparing